Upper Extremity Constant Currency Growth of 11.9% Led by the Aequalis Ascend™ Flex
AMSTERDAM, Netherlands, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Tornier N.V. (NASDAQ:TRNX), a global medical device company focused on providing surgical solutions to orthopaedic extremity specialists, reported today its financial results for the second quarter ended June 28, 2015.
Revenue for the second quarter of 2015 was $83.2 million compared to second quarter 2014 revenue of $86.9 million, a decrease of 4.2% as reported and an increase of 4.0% in constant currency. Foreign currency exchange rates negatively impacted second quarter 2015 reported revenue by $7.1 million.
Second quarter 2015 revenue of Tornier's extremities product categories totaled $71.8 million compared to $71.9 million during the prior year period, a decrease of 0.2% as reported and an increase of 6.0% in constant currency.
Dave Mowry, President and Chief Executive Officer of Tornier, commented, "Our second quarter performance highlights the strong momentum in our upper extremities business, driven by our innovative product portfolio and clinically superior sales team. The Aequalis Ascend™ Flex shoulder system delivered another quarter of above-market growth and we made good progress in our commercial preparations for the recently FDA cleared Simpliciti™ shoulder system. This includes working with key opinion leaders and developing Centers of Excellence for Simpliciti, laying the foundation for the next leg of growth in our upper extremities business as we enter 2016."
Mr. Mowry continued, "As expected, our lower extremities business experienced distractions related to our pending merger with Wright Medical Group, Inc. However, we have been able to retain a high quality sales team and believe we have a very attractive combination of products and people to drive long-term growth for the future combined business. We are confident that the pending merger with Wright will leverage the strengths of both companies to create the premier high growth extremities and biologics company. Subject to FTC clearance, we expect the merger to close in the third quarter and are enthusiastic about the growth and profitability prospects for the combined organization."
The Company's second quarter 2015 adjusted EBITDA, as defined in the GAAP to non-GAAP reconciliation provided later in this release, was $8.3 million, or 9.9% of reported revenue, compared to $6.1 million, or 7.0% of revenue, in the same quarter of the prior year.
Second Quarter 2015 Revenue Highlights
Extremities
-
Revenue from the upper extremities joints and trauma category was $56.6 million, an increase of 11.9% in constant currency over the same quarter in 2014. Growth was led by the Aequalis Ascend family of shoulder joint replacement products, which continued to gain global surgeon acceptance. The consistent performance of our upper extremities joints and trauma category demonstrates the success of the Company's strategy to deliver superior products with a differentiated sales force.
-
Revenue from Tornier's lower extremities joints and trauma category in the second quarter of 2015 reached $12.0 million, a decrease of 13.8% in constant currency. As anticipated, distractions from the Company's pending merger with Wright have impacted results in all segments of the Company's lower extremities business.
- Revenue from the sports medicine and biologics product category was $3.2 million in the second quarter of 2015, a decrease of 3.0% in constant currency over the same quarter in 2014, reflecting a decline in the Company's soft tissue anchor and biologics products.
Large Joints
Constant currency revenue from large joints and other products decreased 5.7% in the second quarter of 2015, reflecting anticipated deceleration in Europe and a challenging comparison to the prior year period, which benefitted from the launch of new minimally invasive hip instrumentation.
Geographic Revenue
On a geographic basis as compared to the second quarter of 2014, Tornier's international revenue decreased 12.9% as reported and increased 5.7% in constant currency, representing 39.8% of reported global revenue. Revenue in the United States increased by 2.6% and represented 60.2% of reported global revenue.
Fiscal Year 2015 Outlook
Due to the anticipated closing of the Wright merger, which is expected to take place in the third quarter, Tornier will no longer be providing financial guidance. Tornier expects that its upper extremities joints and trauma category will continue to make strong and consistent contributions to the anticipated combined business and that its lower extremities joints and trauma category will enhance the already robust Wright lower extremities business over the long term.
Forward-Looking Statements
Statements contained in this release that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations of future events and often can be identified by words such as "believe," "expect," "should," "anticipate," "intend," "will," "can," "may," "could," "continue," "outlook," "future, other words of similar meaning or the use of future dates. Examples of forward-looking statements in this release include Tornier's expectations for the timing of the Wright merger, the future contributions of its upper and lower extremities joint and trauma businesses to the combined company and the growth and profitability prospects for the combined company. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Tornier's actual results to be materially different than those expressed in or implied by Tornier's forward-looking statements. For Tornier, such uncertainties and risks include, among others, risks relating to Tornier's pending merger with Wright Medical Group, Inc., including the timing of the transaction; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction, or the terms of such approval; the negative impact of the transaction on Tornier's lower extremities joints and trauma revenue and business; the effects of disruption from the transaction making it more difficult to maintain relationships with employees, customers, vendors and other business partners; other business effects, including the effects of industry, economic or political conditions outside of Wright's or Tornier's control; the failure to realize synergies and cost-savings from the transaction or delay in realization thereof; the businesses of Wright and Tornier may not be combined successfully, or such combination may take longer, be more difficult, time-consuming or costly to accomplish than expected; operating costs and business disruption following completion of the transaction, including adverse effects on employee retention and on Wright's and Tornier's respective business relationships with third parties; transaction costs; actual or contingent liabilities; the adequacy of the combined company's capital resources; and other risks and uncertainties, including Tornier's future operating results and financial performance; Tornier's reliance on its independent sales agencies and distributors to sell its products and the effect on its business and operating results of agency and distributor changes, transitions to direct selling models in certain geographies and the recent transition of its U.S. sales channel towards focusing separately on upper and lower extremity products; fluctuations in foreign currency exchange rates; the effect of global economic conditions; the European sovereign debt crisis and austerity measures; risks associated with Tornier's international operations and expansion; the timing of regulatory approvals and introduction of new products; physician acceptance, endorsement, and use of new products; the effect of regulatory actions, changes in and adoption of reimbursement rates and product recalls; competitor activities; Tornier's manufacturing capacity; Tornier's leverage and access to credit under its credit agreement; and changes in tax and other legislation. More detailed information on these and other factors that could affect Tornier's actual results are described in Tornier's filings with the U.S. Securities and Exchange Commission, including its most recently filed annual report on Form 10-K for the fiscal year ended December 28, 2014 and subsequent quarterly reports on Form 10-Q. Tornier undertakes no obligation to update its forward-looking statements.
About Tornier
Tornier is a global medical device company focused on providing solutions to surgeons who treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot. The Company's broad offering of over 95 product lines includes joint replacement, trauma, sports medicine, and biologic products to treat the extremities, as well as joint replacement products for the hip and knee in certain international markets. Since its founding approximately 70 years ago, Tornier's "Specialists Serving Specialists" philosophy has fostered a tradition of innovation, intense focus on surgeon education, and commitment to advancement of orthopaedic technology stemming from its close collaboration with orthopaedic surgeons and thought leaders throughout the world. For more information regarding Tornier, visit www.tornier.com.
Tornier®, Aequalis®, Aequalis Ascend®, Aequalis Ascend® Flex™, and Simpliciti® are trademarks of Tornier N.V and its subsidiaries, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Use of Non-GAAP Financial Measures
To supplement Tornier's consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), Tornier uses certain non-GAAP financial measures in this release. Reconciliations of the non-GAAP financial measures used in this release to the most comparable U.S. GAAP measures for the respective periods can be found in tables later in this release immediately following the detail of revenue by geography. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for Tornier's financial results prepared in accordance with GAAP.
| Tornier N.V. | ||
| Condensed Consolidated Balance Sheets | ||
| (in thousands) | ||
| June 28, 2015 | December 28, 2014 | |
| (unaudited) | ||
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $ 25,883 | $ 27,940 |
| Accounts receivable, net | 68,046 | 63,583 |
| Inventories | 85,074 | 88,662 |
| Deferred income taxes and other current assets | 30,515 | 29,516 |
| Total current assets | 209,518 | 209,701 |
| Instruments, net | 60,351 | 62,888 |
| Property, plant and equipment, net | 42,558 | 44,662 |
| Goodwill and intangibles, net | 322,701 | 339,902 |
| Deferred income taxes and other assets | 2,371 | 1,422 |
| Total assets | $ 637,499 | $ 658,575 |
| Liabilities and shareholders' equity | ||
| Current liabilities | ||
| Short-term borrowing and current portion of long-term debt | $ 8,264 | $ 7,394 |
| Accounts payable | 20,630 | 15,073 |
| Accrued liabilities, deferred income taxes and other current liabilities | 55,981 | 61,994 |
| Total current liabilities | 84,875 | 84,461 |
| Other long-term debt | 77,308 | 68,105 |
| Deferred income taxes and other long-term liabilities | 25,800 | 27,119 |
| Total liabilities | 187,983 | 179,685 |
| Shareholders' equity | 449,516 | 478,890 |
| Total liabilities and shareholders' equity | $ 637,499 | $ 658,575 |
| Tornier N.V. | ||||
| Consolidated Statements of Operations | ||||
| (in thousands, except per share data) | ||||
| Three Months Ended | Six Months Ended | |||
| (unaudited) | (unaudited) | |||
| June 28, 2015 | June 29, 2014 | June 28, 2015 | June 29, 2014 | |
| Revenue | $ 83,221 | $ 86,850 | $ 171,313 | $ 175,875 |
| Cost of goods sold | 18,689 | 21,069 | 38,673 | 43,271 |
| Cost of goods sold - acquisition related | -- | 158 | -- | 420 |
| Gross profit | 64,532 | 65,623 | 132,640 | 132,184 |
| 77.5% | 75.6% | 77.4% | 75.2% | |
| Operating expenses | ||||
| Selling, general and administrative | 59,118 | 62,504 | 119,206 | 121,352 |
| Research and development | 5,873 | 6,068 | 11,811 | 11,790 |
| Amortization of intangible assets | 4,019 | 4,320 | 8,047 | 8,654 |
| Special charges | 2,466 | 686 | 4,203 | 3,372 |
| Total operating expenses | 71,476 | 73,578 | 143,267 | 145,168 |
| Operating (loss) income | (6,944) | (7,955) | (10,627) | (12,984) |
| Other income (expense) | ||||
| Interest income | 15 | 40 | 18 | 108 |
| Interest expense | (1,455) | (1,365) | (2,752) | (2,714) |
| Foreign currency transaction loss | (428) | (214) | (95) | (43) |
| Other non-operating income | 27 | 7 | 88 | 9 |
| Loss before income taxes | (8,785) | (9,487) | (13,368) | (15,624) |
| Income tax expense | (558) | (961) | (1,091) | (61) |
| Consolidated net loss | $ (9,343) | $ (10,448) | $ (14,459) | $ (15,685) |
| Net loss per share | ||||
| Basic and diluted | $ (0.19) | $ (0.21) | $ (0.29) | $ (0.32) |
| Weighted average ordinary shares outstanding | ||||
| Basic and diluted | 49,081 | 48,612 | 49,035 | 48,568 |
| Tornier N.V. | ||||
| Consolidated Statements of Cash Flow | ||||
| (in thousands) | ||||
| Three Months Ended | Six months ended | |||
| (unaudited) | (unaudited) | |||
| June 28, 2015 | June 29, 2014 | June 28, 2015 | June 29, 2014 | |
| Cash flows from operating activities | ||||
| Consolidated net loss | $ (9,343) | (10,448) | $ (14,459) | $ (15,685) |
| Adjustments to reconcile consolidated net loss to net cash provided by (used in) operating activities | ||||
| Depreciation and amortization | 10,205 | 10,439 | 20,432 | 20,262 |
| Non-cash foreign currency (gain) loss | 419 | 210 | 62 | 39 |
| Deferred income taxes | (866) | (1,410) | (2,876) | (2,581) |
| Share-based compensation | 2,540 | 2,741 | 4,658 | 4,521 |
| Non-cash interest expense and discount amortization | 226 | 141 | 436 | 354 |
| Inventory obsolescence | 3,013 | 2,492 | 5,013 | 5,678 |
| Fair value adjustment of contingent consideration liability | -- | -- | 769 | -- |
| Inventory step up from acquisition | -- | 158 | -- | 420 |
| Other non-cash items affecting earnings | (297) | 244 | 251 | 326 |
| -- | ||||
| Changes in operating assets and liabilities | -- | |||
| Accounts receivable | 6,541 | 1,285 | (6,213) | (3,219) |
| Inventories | (2,661) | (7,894) | (6,493) | (15,326) |
| Accounts payable and accruals | (1,086) | 557 | 3,628 | 8,167 |
| Other current assets and liabilities | (3,865) | (3,069) | (3,465) | (3,347) |
| Other non-current assets and liabilities | (381) | 1,292 | (135) | 496 |
| Net cash provided by (used in) operating activities | 4,445 | (3,262) | 1,608 | 105 |
| Cash flows from investing activities | ||||
| Acquisition-related cash payments | (360) | (5,622) | (360) | (7,622) |
| Additions of instruments | (4,603) | (7,735) | (9,281) | (14,535) |
| Purchases of property, plant and equipment | (1,250) | (3,116) | (3,661) | (4,880) |
| Net cash (used in) investing activities | (6,213) | (16,473) | (13,302) | (27,037) |
| Cash flows from financing activities | ||||
| Contingent consideration payments | (652) | -- | (1,452) | -- |
| Change in short-term debt | (9,000) | -- | 1,000 | -- |
| Repayments of long-term debt | (455) | (189) | (770) | (563) |
| Proceeds from issuance of long-term debt | 4 | 477 | 10,067 | 477 |
| Deferred financing costs | -- | -- | (114) | -- |
| Issuance of ordinary shares | 1,431 | 1,845 | 1,723 | 2,196 |
| Net cash provided by (used in) financing activities | (8,672) | 2,133 | 10,454 | 2,110 |
| Effect of currency exchange rates on cash and cash equivalents | 266 | (40) | (817) | (191) |
| Decrease in cash and cash equivalents | (10,174) | (17,642) | (2,057) | (25,013) |
| Cash and cash equivalents at beginning of period | 36,057 | 49,413 | 27,940 | 56,784 |
| Cash and cash equivalents at end of period | $ 25,883 | $ 31,771 | $ 25,883 | $ 31,771 |
| Tornier N.V. | ||||||
| Selected Revenue Information | ||||||
| (in thousands) | ||||||
| Three Months Ended | Six Months Ended | |||||
| (unaudited) | (unaudited) | |||||
|
June 28, 2015 |
June 29, 2014 |
Percent change |
June 28, 2015 |
June 29, 2014 |
Percent change |
|
| Revenue by product category | ||||||
| Upper extremity joints and trauma | $ 56,572 | $ 53,826 | 5.1% | $ 113,948 | $ 106,881 | 6.6% |
| Lower extremity joints and trauma | 11,971 | 14,469 | -17.3% | 25,905 | 29,542 | -12.3% |
| Sports medicine and biologics | 3,249 | 3,653 | -11.1% | 6,726 | 7,540 | -10.8% |
| Total extremities | 71,792 | 71,948 | -0.2% | 146,579 | 143,963 | 1.8% |
| Large joints and other | 11,429 | 14,902 | -23.3% | 24,734 | 31,912 | -22.5% |
| Total | $ 83,221 | $ 86,850 | -4.2% | $ 171,313 | $ 175,875 | -2.6% |
| Revenue by geography | ||||||
| United States | $ 50,104 | $ 48,848 | 2.6% | $ 103,073 | $ 98,813 | 4.3% |
| International | 33,117 | 38,002 | -12.9% | 68,240 | 77,062 | -11.4% |
| Total | $ 83,221 | $ 86,850 | -4.2% | $ 171,313 | $ 175,875 | -2.6% |
| Tornier N.V. | |||||
| Reconciliation of Revenue to Non-GAAP Revenue on a Constant Currency Basis | |||||
| (in thousands) | |||||
| Three Months Ended | |||||
| (unaudited) | |||||
| June 28, 2015 | June 29, 2014 | ||||
|
Revenue as reported |
Foreign exchange impact as compared to prior period |
Revenue on a constant currency basis |
Revenue as reported |
Percent change on a constant currency basis |
|
| Revenue by product category | |||||
| Upper extremity joints and trauma | $ 56,572 | $ 3,657 | $ 60,229 | $ 53,826 | 11.9% |
| Lower extremity joints and trauma | 11,971 | 498 | 12,469 | 14,469 | -13.8% |
| Sports medicine and biologics | 3,249 | 294 | 3,543 | 3,653 | -3.0% |
| Total extremities | 71,792 | 4,449 | 76,241 | 71,948 | 6.0% |
| Large joints and other | 11,429 | 2,621 | 14,050 | 14,902 | -5.7% |
| Total | $ 83,221 | $ 7,070 | $ 90,291 | $ 86,850 | 4.0% |
| Revenue by geography | |||||
| United States | $ 50,104 | $ -- | $ 50,104 | $ 48,848 | 2.6% |
| International | 33,117 | 7,070 | 40,187 | 38,002 | 5.7% |
| Total | $ 83,221 | $ 7,070 | $ 90,291 | $ 86,850 | 4.0% |
| Six Months Ended | |||||
| (unaudited) | |||||
| June 28, 2015 | June 29, 2014 | ||||
|
Revenue as reported |
Foreign exchange impact as compared to prior period |
Revenue on a constant currency basis |
Revenue as reported |
Percent change on a constant currency basis |
|
| Revenue by product category | |||||
| Upper extremity joints and trauma | $ 113,948 | $ 6,797 | $ 120,745 | $ 106,881 | 13.0% |
| Lower extremity joints and trauma | 25,905 | 931 | 26,836 | 29,542 | -9.2% |
| Sports medicine and biologics | 6,726 | 555 | 7,281 | 7,540 | -3.4% |
| Total extremities | 146,579 | 8,283 | 154,862 | 143,963 | 7.6% |
| Large joints and other | 24,734 | 5,291 | 30,025 | 31,912 | -5.9% |
| Total | $ 171,313 | $ 13,574 | $ 184,887 | $ 175,875 | 5.1% |
| Revenue by geography | |||||
| United States | $ 103,073 | $ -- | $ 103,073 | $ 98,813 | 4.3% |
| International | 68,240 | 13,574 | 81,814 | 77,062 | 6.2% |
| Total | $ 171,313 | $ 13,574 | $ 184,887 | $ 175,875 | 5.1% |
| Tornier N.V. | ||||
| Reconciliation of Net Loss to | ||||
| Non-GAAP Adjusted Earnings Before Interest, Taxes, Depreciation | ||||
| and Amortization (EBITDA) | ||||
| (in thousands) | ||||
| Three Months Ended | Six Months Ended | |||
| (unaudited) | (unaudited) | |||
| June 28, 2015 | June 29, 2014 | June 28, 2015 | June 29, 2014 | |
| Revenue, as reported | $ 83,221 | $ 86,850 | $ 171,313 | $ 175,875 |
| Net loss, as reported | $ (9,343) | $ (10,448) | $ (14,459) | $ (15,685) |
| Interest income | (15) | (40) | (18) | (108) |
| Interest expense | 1,455 | 1,365 | 2,752 | 2,714 |
| Income tax expense (benefit) | 558 | 961 | 1,091 | 61 |
| Depreciation | 6,186 | 6,119 | 12,385 | 11,608 |
| Amortization | 4,019 | 4,320 | 8,047 | 8,654 |
| Subtotal Non-GAAP EBITDA | 2,860 | 2,277 | 9,798 | 7,244 |
| Other non-operating (income) expense | (27) | (7) | (88) | (9) |
| Foreign currency transaction loss (gain) | 428 | 214 | 95 | 43 |
| Share-based compensation | 2,540 | 2,741 | 4,658 | 4,521 |
| Inventory step-up from acquisition | -- | 158 | -- | 420 |
| Special Charges: | ||||
| Acquisition, integration and distribution transition costs | (106) | 123 | 818 | 2,036 |
| Instrument use tax refund | -- | (2,000) | -- | |
| Restructuring | -- | 563 | -- | 1,011 |
| Proposed merger-related costs | 2,572 | -- | 5,385 | -- |
| Other | -- | -- | -- | 325 |
| Non-GAAP adjusted EBITDA | $ 8,267 | $ 6,069 | $ 18,666 | $ 15,591 |
| Non-GAAP adjusted EBITDA margin | 9.9% | 7.0% | 10.9% | 8.9% |
| Tornier N.V. | ||||
| Reconciliation of Net Loss and Loss per Share | ||||
| to Adjusted Net Loss and Adjusted Net Loss per Share | ||||
| (in thousands) | ||||
| Three Months Ended | Six Months Ended | |||
| (unaudited) | (unaudited) | |||
| June 28, 2015 | June 29, 2014 | June 28, 2015 | June 29, 2014 | |
| Net loss, as reported | $ (9,343) | $ (10,448) | $ (14,459) | $ (15,685) |
| Inventory step-up from acquisition, net of tax | -- | 153 | -- | 403 |
| Reversal of valuation allowance from acquisition | -- | (146) | -- | (146) |
| Special charges, net of tax: | ||||
| Acquisition, integration and distribution transition costs | (106) | 123 | 818 | 1,011 |
| Instrument use tax refund | -- | -- | (2,000) | -- |
| Restructuring | -- | 563 | -- | 2,036 |
| Proposed merger-related costs | 2,572 | -- | 5,385 | -- |
| Other | -- | -- | -- | 325 |
| Non-GAAP adjusted net loss | (6,877) | (9,755) | (10,256) | (12,056) |
| Net loss per share, as reported | ||||
| Basic and diluted | $ (0.19) | $ (0.21) | $ (0.29) | $ (0.32) |
| Inventory step-up from acquisition, net of tax | -- | 0.00 | -- | 0.01 |
| Reversal of valuation allowance from acquisition | -- | (0.00) | -- | (0.00) |
| Special charges, net of tax: | ||||
| Acquisition, integration and distribution transition costs | (0.00) | -- | 0.02 | 0.02 |
| Instrument use tax refund | -- | -- | (0.05) | -- |
| Restructuring | -- | 0.01 | -- | 0.03 |
| Proposed merger-related costs | 0.05 | -- | 0.11 | -- |
| Other | -- | -- | -- | 0.01 |
| Non-GAAP adjusted net loss per share | ||||
| Basic and diluted | $ (0.14) | $ (0.20) | $ (0.21) | $ (0.25) |
| Weighted average ordinary shares outstanding | ||||
| Basic and diluted | 49,081 | 48,612 | 49,035 | 48,568 |
| Tornier N.V. | ||||
| Reconciliation of Net Cash Provided by Operating Activities | ||||
| to Non-GAAP Free Cash Flow | ||||
| (in thousands) | ||||
| Three Months Ended | Six Months Ended | |||
| (unaudited) | (unaudited) | |||
| June 28, 2015 | June 29, 2014 | June 28, 2015 | June 29, 2014 | |
| Net cash provided by operating activities, as reported | $ 4,445 | $ (3,262) | $ 1,608 | $ 105 |
| Adjusted for: | ||||
| Additions of instruments, as reported | (4,603) | (7,735) | (9,281) | (14,535) |
| Purchases of property, plant and equipment, as reported | (1,250) | (3,116) | (3,661) | (4,880) |
| Non-GAAP adjusted free cash flow | $ (1,408) | $ (14,113) | $ (11,334) | $ (19,310) |
| Tornier N.V. | ||||
| Reconciliation of Gross Margin and Gross Margin % | ||||
| to Non-GAAP Adjusted Gross Margin and Gross Margin % | ||||
| (in thousands) | ||||
| Three Months Ended | Six months ended | |||
| (unaudited) | (unaudited) | |||
| June 28, 2015 | June 29, 2014 | June 28, 2015 | June 29, 2014 | |
| Revenue, as reported | $ 83,221 | $ 86,850 | $ 171,313 | $ 175,875 |
| Gross margin, as reported | $ 64,532 | $ 65,623 | $ 132,640 | $ 132,184 |
| Gross margin %, as reported | 77.5% | 75.6% | 77.4% | 75.2% |
| Adjusted for: | ||||
| Inventory step-up due to acquisition | -- | 158 | -- | 420 |
| Non-GAAP adjusted gross margins | 64,532 | 65,781 | 132,640 | 132,604 |
| Non-GAAP adjusted gross margin % | 77.5% | 75.7% | 77.4% | 75.4% |
| Tornier N.V. | ||||
| Reconciliation of Operating Expenses to | ||||
| Non-GAAP Adjusted Operating Expenses | ||||
| Three Months Ended | Six months ended | |||
| (unaudited) | (unaudited) | |||
| June 28, 2015 | June 29, 2014 | June 28, 2015 | June 29, 2014 | |
| Revenue, as reported | $ 83,221 | $ 86,850 | $ 171,313 | $ 175,875 |
| Operating Expenses, as reported | 71,476 | 73,578 | 143,267 | 145,168 |
| Operating expenses as a percentage of revenue, as reported | 85.9% | 84.7% | 83.6% | 82.5% |
| Adjusted for: | ||||
| Amortization of intangible assets | (4,019) | (4,320) | (8,047) | (8,654) |
| Special charges | (2,466) | (686) | (4,203) | (3,372) |
| Total adjustments | (6,485) | (5,006) | (12,250) | (12,026) |
| Non-GAAP adjusted operating expenses | $ 64,991 | $ 68,572 | $ 131,017 | $ 133,142 |
| Non-GAAP adjusted operating expenses as a percentage of revenue | 78.1% | 79.0% | 76.5% | 75.7% |
Tornier believes the non-GAAP financial measures presented above provide additional meaningful information for measuring Tornier's financial performance and are measures frequently used by Tornier's management, as well as securities analysts and investors. Tornier uses the non-GAAP financial measures as supplemental measures of its performance and believes such measures facilitate operating performance comparisons from period to period and company to company by factoring out potential differences caused by charges not related to Tornier's regular, ongoing business, including non-cash charges, certain large and unpredictable charges, acquisitions, dispositions, litigation settlements and tax positions. Tornier's management uses the non-GAAP financial measures to assess the performance of Tornier's core operations, analyze underlying trends in Tornier's businesses, establish operational goals and forecasts, and evaluate Tornier's performance period over period and in relation to the operating results of its competitors. Tornier's management uses the non-GAAP financial measures to help allocate its resources to both ongoing and prospective business initiatives and to help make budgeting and spending decisions, for example, between product development expenses, research and development expenses, and selling, general and administrative expenses. Tornier's management is evaluated on the basis of several of these non-GAAP financial measures when determining achievement of performance incentive compensation goals.
Tornier believes that non-GAAP financial measures have limitations as analytical tools since they do not reflect all of the amounts associated with Tornier's operating results as determined in accordance with GAAP and should only be used to evaluate Tornier's operating results in conjunction with the corresponding GAAP measures. Accordingly, revenue on a constant currency basis should not be used as a substitute for revenue, EBITDA, adjusted EBITDA, adjusted net income (loss) and adjusted net income (loss) per share should not be used as a substitute for net income or net income per share; adjusted EBITDA margin should not be used as a substitute for net margin or operating margin; free cash flow should not be used as a substitute for cash flows from operations; and adjusted gross margin and gross margin percentage should not be used as a substitute for gross margin or gross margin as a percentage of revenue, in each case as determined in accordance with GAAP. Neither EBITDA, adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted net income (loss) per share, free cash flow, adjusted gross margin and gross margin as a percentage of revenue, should be an indication of whether cash flow will be sufficient to fund Tornier's cash requirements. Additionally, the calculation of non-GAAP financial measures is not based on any comprehensive or standard set of accounting rules or principles. Accordingly, Tornier's definitions of revenue on a constant currency basis, EBITDA, adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted net income (loss) per share, free cash flow, adjusted gross margin and gross margin as a percentage of revenue, may differ from the definitions of other companies using the same or similar names limiting, to some extent, the usefulness of such measures for comparison purposes.
For further information regarding why Tornier believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to Tornier's current report on Form 8-K filed today with the Securities and Exchange Commission which attaches this release as an exhibit. This current report on Form 8-K is available on the SEC's website at www.sec.gov or on Tornier's website at www.tornier.com.